How is gallbladder cancer staged according to the AJCC 8th edition TNM system and what are the treatment recommendations for each stage?

Gallbladder Cancer Staging and Treatment

Gallbladder cancer should be staged according to the TNM 2010 system (which corresponds to AJCC 7th edition), as this is the staging system explicitly referenced in the available ESMO guidelines, though the AJCC 8th edition is now in clinical use and provides improved prognostic stratification. 1

TNM Staging System Components

Primary Tumor (T) Classification

The T staging for gallbladder cancer follows this progression 1:

• Tis: Carcinoma in situ
• T1a: Tumor invades lamina propria
• T1b: Tumor invades muscular layer
• T2: Tumor invades perimuscular connective tissue; no extension beyond serosa or into liver
• T3: Tumor perforates the serosa (visceral peritoneum) and/or directly invades the liver and/or one other adjacent organ or structure (stomach, duodenum, colon, pancreas, omentum, or extrahepatic bile ducts)
• T4: Tumor invades main portal vein or hepatic artery or invades two or more extrahepatic organs or structures

Regional Lymph Node (N) Classification

The N staging is defined as 1:

• N0: No regional lymph node metastasis
• N1: Metastases to nodes along the cystic duct, common bile duct, hepatic artery and/or portal vein
• N2: Metastases to periaortic, pericaval, superior mesenteric artery and/or celiac artery lymph nodes

Important Staging Considerations

The AJCC 8th edition introduced refinements that improve prognostic discrimination, particularly for node-positive disease, with a concordance index of 0.832. 2 Research validates that the 8th edition better stratifies survival, though some modifications may further optimize staging accuracy 3, 4, 5.

Staging Workup Requirements

Complete staging must include 1:

• Complete history and physical examination
• Blood counts and liver function tests
• Chest X-ray
• Abdominal imaging: CT scan or MRI with sonography
• Endoscopic retrograde or percutaneous transhepatic cholangiography
• Consider: Endoscopic ultrasonography, cholangioscopy, and laparoscopy for resectability assessment

For biliary tract cancers, MRI is the reference examination for local extension, while thoraco-abdomino-pelvic CT remains the reference for lymph node and metastatic extension. 1

Treatment Recommendations by Stage

Stage 0 and Stage I (Tis, T1a, T1b, N0, M0)

For T1a tumors (lamina propria invasion): Simple cholecystectomy is sufficient if the gallbladder was removed intact; observation only is recommended with no benefit from re-resection. 1, 6

For T1b tumors (muscle layer invasion) or greater: Radical re-resection is highly recommended after complete staging including laparoscopy demonstrating resectability. 1

• Simple cholecystectomy shows no survival difference compared to radical cholecystectomy for stages 0 and I 6
• Extended cholecystectomy includes en bloc hepatic resection and lymphadenectomy with or without bile duct excision 1

Stage II (T2, N0, M0)

Radical cholecystectomy is superior to simple cholecystectomy for stage II patients and should be the standard approach. 6

• Radical cholecystectomy involves wedge resection of the gallbladder fossa with 2 cm non-neoplastic liver tissue 6
• Extended portal lymph node dissection should be performed 6
• Resection of suprapancreatic segment of extrahepatic bile duct may be considered based on individual circumstances 6

Stage III (T3-T4 and/or N1-N2)

For stage III patients, radical cholecystectomy is significantly superior to other surgical options and should be actively pursued. 6

Adjuvant fluorouracil-based chemotherapy is associated with a small survival benefit after non-curative resection. 1

• Postoperative chemoradiotherapy may be considered as an option, given the high incidence of local failure (52%) after surgical resection 1
• Gemcitabine with or without oxaliplatin has shown feasibility with radiotherapy 1

Important caveat: Research suggests T3 disease may benefit from subdivision into T3a (serosa perforation without organ invasion) and T3b (with organ invasion), as T3b patients have significantly worse survival (median 13 vs 26 months) and may require extended radical resection 7.

Stage IVA (T4 or any N2)

For stage IVA patients, radical cholecystectomy is not superior to palliative resection and non-surgical treatment; palliative approaches should be considered. 6

• N2 disease classification remains controversial, as some patients with N2 disease can undergo R0 resection with survival superior to M1 disease 4
• Palliation of jaundice can be accomplished by endoscopic or percutaneous stenting or operative biliary-enteric bypass 1

Stage IVB (M1 disease)

Palliative resection significantly improves survival compared to non-surgical treatment for stage IVB patients. 6

• Systemic chemotherapy with gemcitabine plus cisplatin or oxaliplatin is the standard approach for unresectable disease 1
• Monotherapy with 5-fluorouracil or gemcitabine should be considered when combination therapy is not applicable 1

Critical Pitfalls and Caveats

Lymph node sampling remains inadequate in clinical practice: only 50.7% of patients undergo any lymph node sampling, and only 24.5% of those sampled meet the ≥6 lymph node threshold recommended by AJCC 8th edition. 2 This represents a major quality gap requiring improvement.

For patients without nodal dissection (NX), survival falls between N0 and N1 cases, necessitating close postoperative follow-up. 3

The AJCC 8th edition staging system shows some survival reversals (stage IIIA worse than IIIB in some cohorts), suggesting further refinement may be needed. 4

Incidental gallbladder cancer found at surgery requires intraoperative staging and immediate consideration of extended cholecystectomy depending on resectability and surgical expertise. 1